Drug associated hepatic reactions in New Zealand: 21 years experience

New Zealand Medical Journal

Volumn 109, Issue 1028, 1996, Pages 315-319

  Pillans, Peter I ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; BEZAFIBRATE; CAPTOPRIL; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; COTRIMOXAZOLE; DICLOFENAC; DOSULEPIN; ERYTHROMYCIN; FLUCLOXACILLIN; FLUOXETINE; HALOTHANE; KETOCONAZOLE; METHYLDOPA; MIANSERIN; MINOCYCLINE; NITROFURANTOIN; OXYPHENBUTAZONE; PERHEXILINE; PHENYTOIN; RANITIDINE; ROXITHROMYCIN; SIMVASTATIN; TROLEANDOMYCIN; VALPROIC ACID;

ARTICLE; FEMALE; HEPATITIS; HUMAN; INCIDENCE; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANESTHETICS, INHALATION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; CLAVULANIC ACIDS; DICLOFENAC; DRUG THERAPY; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; FEMALE; FLOXACILLIN; HALOTHANE; HUMANS; LIVER; MALE; MIDDLE AGED; NEW ZEALAND; PENICILLINS; PERHEXILINE; STEROIDS;

EID: 0029800092     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lee WM. Review article: drug-induced hepatotoxicity. Aliment Pharmacol Ther 1993; 7: 477-85.
2. Peasayre D, Larrey D. Drug-induced liver injury. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford University Press, 1991: 875-902.
3. Farrell GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994.
4. Report of an international consensus meeting. Drug-induced liver disorders: standardization of definitions and criteria of causality assessment of adverse drug reactions. Int J Clin Pharmacol Ther 1990; 28: 317-22.
5. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Safety 1993; 9: 441-9.
6. Jick H, Walker AM, Porter J Drug-induced liver disease. J Clin Pharmacol 1981; 21: 359-64.
7. Hallas H, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61-8.
8. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987.J Intern Med 1992; 232: 133-8.
9. Bottiger LE, Furhoff AK, Holmberg L. Fatal reactions to drugs. A 10-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 1979; 205: 451-6.
10. Zimmerman HJ, Maddrey WC. Toxic and drug induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the liver. Philadelphia: Lippincott, 1993: 707-83.
11. Lewis JH, Zimmerman HJ. Drug-induced liver disease. Med Clin North Am 1989; 73: 775-92.
12. Dossing M, Andreasen PB. Drug induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982; 17: 205-11.
13. Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth 1991; 67: 84-9.
14. Kenna JG, Knight TL, van Pelt FNAM. Immunity of halothane metabolite-modified proteins in halothane hepatitis. Ann NY Acad Sci 1993; 685: 646-61.
15. Smith GCM, Kenna JG, Harrison DJ, Tew D, Wolf CR. Autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis. Lancet 1993; 342: 963-4.
16. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated choleatatic hepatitis. Med J Aust 1993; 158: 600-2.
17. Avila P, Capella D, Laporte JR, Moreno V. Which salt of erythromycin is most hepatotoxic. Lancet 1988; 1: 1104.
18. Inman WHW, Rawson NSB. Erythromycin estolate and jaundice. BMJ 1983; 286: 1954-5
19. Pillans P, Maling T. Roxithromycin and hepatitis. Drug Invest 1993; 6: 296-9.
20. Garcia Rodriguez LA, Gutthann SP, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305: 865-8.
21. Carson JL, Duff A, Strom BL. Drug-induced acute liver disease. Pharmacoepidemiol Drug Safety 1993; 2: S19-23.
22. Askmark H, Wiholm B. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneously reporting system. Acta Neurol Scand 1990; 81: 131-40.
23. Williams SJ, Ruppin DC, Grierson JM, Farrell GC. Carbamazepine hepatitis: the clinicopathological spectrum. J Gastroenterol Hepatol 1986; 1: 159-68.
24. Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterol 1992; 102: 1385-8.
25. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33: 368-71.
26. Ryley NG, Fleming KA, Chapman RWG. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995; 23: 278-82.
27. Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 153: 596-600.
28. Fairley CK, McNeil JJ, Desmond P, Smallwood R, Young H, Forbes A, et al. Risk factors for development of flucloxacillin associated jaundice. BMJ 1993; 306: 233-5.
29. Devereux BM, Crawford DHG, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated Cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995; 49: 81-5.